HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

BIO: Bio Rad Laboratories Cl A - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

BIO RAD LABORATORIES CL A (NYSE)
BIO 97.34 -0.19 (-0.19%) Vol.  58,691 16:02 ET

Day Low - High 96.40 - 98.43
52wk Low - High 51.33 - 98.43
Avg Volume 65,010
Industry MED PRODUCTS
Market Cap 2.67 B
Div - Yield 0.00 - 0.00
PE (forward) 21.05
PEG Ratio 1.87
Current Year Est. 4.62
EPS Last Year 5.03
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


downgraded 10/27/2009
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/05/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
BIO RAD LABORATORIES CL A BIO PREMIUM
QUIDEL CORP QDEL PREMIUM
CONCEPTUS INC CPTS PREMIUM
ORASURE TECH OSUR PREMIUM
See all MED PRODUCTS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.67
ABR (Last Week) 1.67
# of Recs in ABR 3
Average Target Price 95.67
Industry Rank by ABR 57 out of 217
Rank in Industry 22 out of 71
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate BIO?
Buy
Sell
Find out what the Zacks Community
thinks of BIO at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR BIO
Zacks Equity Research: Report for BIO
Nov 05, 2009
Zacks Blog: Zacks Releases Four Powerful ''Buy'' Stocks: Cantel Medical Corp, Avon Products Inc., Bio-Rad Laboratories, Inc. and Par Pharmaceutical Companies, Inc.
Oct 20, 2009
Momentum: Bio-Rad Laboratories, Inc.
Oct 20, 2009
Zacks Blog: Zacks #1 Rank Additions for Tuesday
Oct 06, 2009
Zacks Blog: Zacks #5 Rank Additions for Tuesday
Jul 21, 2009
More Zacks Commentary
NEWS
Bio-Rad Laboratories Up 27% Since SmarTrend's Buy Recommendation
Nov 04, 2009
Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 11Percent
Nov 03, 2009
Conference Calls Today: 5-5:30 P.M. EDT
Nov 03, 2009
Biotest agrees sale of diagnostics business to Bio-Rad
Oct 27, 2009
PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts, October 23, 2009: RTN, TRV, PGH, BWA, KKD and BIO
Oct 23, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 1.03 1.15 4.62 4.92
Number of Estimates 3 1 3 3
Low Estimates 0.95 1.15 4.33 4.60
High Estimate 1.14 1.15 4.99 5.45
Year Ago EPS 1.18 1.10 4.71 4.62
EPS Growth -12.71% 4.55% -1.84% 6.34%

More Estimates

COMPANY DESCRIPTION
Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California.

Full Company Report
FINANCIALS
EPS TTM 5.03
Sales 1764.36
Net Income 98.54
Price/Earnings 19.35
Price/Book 2.36
Price/Cash Flow 20.48
Price/Sales 1.54


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research